Germline RET proto-oncogene mutations in two Taiwanese families with multiple endocrine neoplasia type 2A

Journal of the Formosan Medical Association

Volumn 97, Issue 9, 1998, Pages 614-618

  Wu, Shih Lu ^a   Chang, Tien Chun ^b,d   Huang, Chien Ning ^b   Chuang, Lee Ming ^b   Chang, Tien Jye ^c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Heterozygote; Homozygote; Multiple endocrine neoplasia; RET proto oncogene; Type 2A

Indexed keywords

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CODON; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EXON; FEMALE; GENE MUTATION; HUMAN; MALE; NUCLEOTIDE SEQUENCE; POINT MUTATION; POLYMERASE CHAIN REACTION; SIPPLE SYNDROME;

DROSOPHILA PROTEINS; FEMALE; GERM-LINE MUTATION; HUMANS; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; PROTO-ONCOGENES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 0031720359     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Raue F, Frank-Raue K, Grauer A: Multiple endocrine neoplasia type 2: clinical features and screening. Endocrinol Metab Clin North Am 1994;23:137-56.
2. Mathew CG, Chin KS, Easton DF, et al: A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 1987;328:527-8.
3. Norum RA, Lafreniere RG, O'Neal LW, et al: Linkage of the multiple endocrine neoplasia type 2B gene (MEN2B) to chromosome 10 markers linked to MEN2A. Genomics 1990;8:313-7.
4. Lairmore TC, Howe JR, Korte JA, et al: Familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2B map to the same region of chromosome 10 as multiple endocrine neoplasia type 2A. [published erratum appears in Genomics 1991;10:514.] Genomics 1991;9:181-92.
5. Mulligan LM, Kwok JBJ, Healey CS, et al: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-60.
6. Donis-Keller H, Dou S, Chi D, et al: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-6.
7. Mulligan LM, Eng C, Healey CS, et al: Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994;6:70-4.
8. Tsai MS, Ledger GA, Khosla S, et al: Identification of multiple endocrine neoplasia, type 2 gene carriers using linkage analysis and analysis of the RET proto-oncogene. J Clin Endocrinol Metab 1994;78:1261-4.
9. Mulligan LM, Eng C, Healey CS, et al: A de novo mutation of the RET proto-oncogene in a patient with MEN 2A. Hum Mol Genet 1994;3:1007-8.
10. Schuffenecker I, Ginet N, Goldgar D, et al: Prevalence and parental origin of de novo RET mutation in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Am J Hum Genet 1997;60:233-7.
11. Santoro M, Carlomagno F, Romano A, et al: Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science 1995;267:381-3.
12. Santoro M, Rosati R, Grieco M, et al: The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene 1990;5:1595-8.
13. Takahashi M, Buma Y, Iwamoto T, et al: Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 1988;3:571-8.
14. Kwok JBJ, Gardner E, Warner JP, et al: Structural analysis of the human ret proto-oncogene using exon trapping. Oncogene 1993;8:2575-82.
15. Frank-Raue K, Höppner W, Frilling A, et al: Mutations of the ret proto-oncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. J Clin Endocrinol Metab 1996;81:1780-3.
16. Feldmann GL, Kambouris M, Talpos GB, et al: Clinical value of direct DNA analysis of the RET proto-oncogene in families with multiple endocrine neoplasia type 2A. Surgery 1994;116:1042-7.
17. Ledger GA, Khosla S, Lindor NM, et al: Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II. Ann Intern Med 1995;122:118-24.
18. Quadro L, Panariello L, Salvatore D, et al: Frequent RET proto-oncogene mutations in multiple endocrine neoplasia type 2A. J Clin Endocnnol Metab 1994;79: 590-4.
19. Wells SA Jr, Chi DD, Toshima K, et al: Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994;220:237-50.
20. Schuffenecker I, Billaud M, Calender A, et al: RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet 1994;3:1939-43.
21. Huang CN, Wu SL, Chang TC, et al: RET proto-oncogene mutations in patients with apparently sporadic medullary thyroid carcinoma. J Formos Med Assoc 1998;8:541-6.
22. Lips CJ, Landsvater RM, Höppener JW, et al: Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994; 331:828-35.
23. Takahashi M, Buma Y, Hiai H: Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence. Oncogens 1989;4:805-6.
24. Marsh DJ, Learoyd DL, Robinson BG: Medullary thyroid carcinoma: recent advances and management update. Thyroid 1995;5:407-24.